^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CVGBM

i
Other names: CVGBM, CV09050101
Associations
Trials
Company:
CureVac
Drug class:
Immunostimulant, Tumor-associated antigen inhibitor
Related drugs:
Associations
Trials
5ms
Enrollment open
|
CVGBM
10ms
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma (clinicaltrials.gov)
P1, N=16, Active, not recruiting, CureVac | Recruiting --> Active, not recruiting | N=54 --> 16
Enrollment closed • Enrollment change
|
IDH wild-type
|
CVGBM
1year
TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (EANO 2023)
In addition to the primary safety objectives, secondary objectives of efficacy (progression-free survival, overall survival) and patient-reported quality of life outcomes will be assessed. Trial sponsor: CureVac SE, Germany.
Clinical • P1 data • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
|
TMB-L • HLA-A*02:01 • HLA-A*02 • IDH wild-type
|
CVGBM
over1year
New P1 trial
|
IDH wild-type
|
CVGBM